In: General Physiology and Biophysics, vol. 39, no. 3
Jaroslav Hrenak - Stefan Zorad - Fedor Simko
Year, pages: 203 - 204
Renin-angiotensin system (RAS) inhibition supposedly increases the expression of angiotensin converting enzyme 2, serving as a binding site for SARS-CoV-2. Concerns arose regarding therapy with RAS inhibition during the COVID-19 pandemic. However, the pharmacological restraining the classical RAS axis might be beneficial due to the reduction of deleterious effects of angiotensin II and enhancement of the anti-inflammatory angiotensin 1-7 pathway. Unless large controlled studies are performed, RAS inhibition remains the cornerstone therapy in populations with cardiovascular disorders.
Publisher: Institute of Molecular Physiology and Genetics SAS